Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
Christina Selinger(Royal Prince Alfred Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre)
Cited by 150
Related Papers
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
|The Lancet Oncology|2017|647
Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
|Cancer Immunology Research|2018|127
Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells
|Molecular Cancer Research|2011|61